CEBPD and metabolic dysfunction-associated steatotic liver disease: In clinical NAFLD datasets (GSE58979 and GSE63067), CEBPD expression was significantly elevated in NAFLD patients compared to healthy controls (p < 0.05), while SOCS2, THBS1, and IFIT2 levels showed no significant changes.